GSK partners with Hengrui Pharma to develop innovative respiratory and oncology treatments

GSK and China’s Hengrui Pharma have entered into agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology, with GSK paying $500 million in upfront fees. Why it matters: The collaboration marks a significant investment in the future of pharmaceutical advancements, leveraging GSK’s global presence and research capabilities and Hengrui’s […] The post GSK partners with Hengrui Pharma to develop innovative respiratory and oncology treatmen...